Figure 2.

Hazard ratios (95% CIs) for the effectiveness outcome^a by eGFR category; within each eGFR category, warfarin initiation was considered as the reference category in estimating the hazard ratios and their 95% CI.

Meta-regression showed that the association between rivaroxaban initiation (compared with warfarin initiation) and the effectiveness outcome was not modified by eGFR category (P = 0.75).

^aDefined as the composite of all-cause death, ischemic stroke, or transient ischemic attack.

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; EXTEND45, Examining Outcomes in Chronic Disease in the 45 and Up Study (the data source used in the state of New South Wales, Australia. In EXTEND45, there were no rivaroxaban–warfarin matched pairs included for eGFR <30 mL/min/1.73 m²); PROMIS, Patient Records and Outcome Management Information System (data source used in the province of British Columbia, Canada; PROMIS is an integrated registry and clinical information system for chronic kidney disease [eGFR <60 mL/min/1.73 m²] and therefore was excluded from eGFR category ≥60 mL/min/1.73m²); S, number of outcome events were <5 and cells were suppressed to meet privacy restrictions.